Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates: A Randomized Controlled Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Red Blood Cells(RBC)
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- death rate
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Acute respiratory distress syndrome (ARDS) in neonates has been defined in 2017.
The death rate is over 50%.There are no special treatments for acute respiratory distress syndrome.
Detailed Description
Acute respiratory distress syndrome (ARDS) is one of the serious complications in critically ill neonates. It can result in severe hypoxemia refractory to mechanical ventilation. There are few options for mechanical ventilation for such situations such as high frequency oscillation ventilation and extracorporeal membrane oxygenation. The aim of the present study is to determine whether transfusion of red blood cells can decrease the mortality in neonate with ARDS.
Investigators
Ma Juan
director
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Eligibility Criteria
Inclusion Criteria
- •diagnosed with neonatal ARDS.
- •informed parental consent has been obtained
Exclusion Criteria
- •major congenital malformations or complex congenital heart disease
- •transferred out of the neonatal intensive care unit without treatment
Outcomes
Primary Outcomes
death rate
Time Frame: within 100 days
neonate died due to respiratory failure